Immunogenicity screening in protein drug development

  • Van Walle I
  • Gansemans Y
  • Parren P
 et al. 
  • 48

    Readers

    Mendeley users who have this article in their library.
  • 53

    Citations

    Citations of this article.

Abstract

Most therapeutic proteins in clinical trials or on the market are, to a variable extent, immunogenic. Formation of antidrug antibodies poses a risk that should be assessed during drug development, as it possibly compromises drug safety and alters pharmacokinetics. The generation of these antibodies is critically dependent on the presence of T helper cell epitopes, which have classically been identified by in vitro methods using blood cells from human donors. As a novel development, in silico methods that identify T cell epitopes have been coming on line. These methods are relatively inexpensive and allow the mapping of epitopes from virtually all human leukocyte antigen molecules derived from a wide genetic background. In vitro assays remain important, but guided by in silico data they can focus on selected peptides and human leukocyte antigen haplotypes, thereby significantly reducing time and cost.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • Ivo Van Walle

  • Yannick Gansemans

  • Paul WHI Parren

  • Philippe Stas

  • Ignace Lasters

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free